EMEA-002631-PIP01-19-M01

Table of contents

Key facts

Active substance
Tapotoclax
Therapeutic area
Oncology
Decision number
P/0123/2022
PIP number
EMEA-002631-PIP01-19-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of acute myeloid leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries
Amgen Europe B.V

Tel.: +44 (0)1223 420305
E-mail: medinfointernational@amgen.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating